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Histopathology of the lungs of mice treated with CVT-6883. Lungs 
were collected from postnatal day 38 mice and prepared routinely for 
sectioning and H&E staining. (A) Lung from an ADA+ mouse treated 
with vehicle. (B) Lung from an ADA+ mouse treated with CVT-6883. 
(C) Lung from an ADA–/– mouse treated with vehicle. (D) Lung from an 
ADA–/– mouse treated with CVT-6883. Sections are representative of 
6–8 different mice from each treatment group. Scale bars: 100 μm.      
Figure 1
Pharmacological characterization of CVT-6883 as an A2BAR 
antagonist. (A) Structure of CVT-6883. (B) Competition of 
CVT-6883 for specific radioligand binding to membranes pre-
pared from CHO cells overexpressing the A1AR or A3AR or 
from HEK cells over-expressing the A2AAR or A2BAR. Increas-
ing concentrations of CVT-6883 were used to displace the 
specific binding of selective receptor radioligands: 3H-CPX 
(A1AR antagonist; 0.45 nM), 3H-ZM241385 (A2AAR antago-
nist; 1.6 nM), 3H-ZM241385 (A2BAR antagonist; 9.3 nM), or 
3H-MRE3008F20 (A3AR antagonist; 0.63 nM). Data are pre-
sented as mean ± SEM percent specific binding of control 
from 6 determinations. (C) Concentration response curves of 
NECA-induced increases in cAMP in the absence or presence 
of increasing concentrations of CVT-6883. Mouse NIH/3T3 
cells were treated with NECA (1 nM to 100 μM) in the absence 
or presence of increasing concentrations of CVT-6883, and 
cAMP accumulation was measured. Data are mean ± SEM 
from 3 experiments performed in duplicate. Inset is the Schild 
plot. DR – 1, concentration ratio minus 1.    
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Airway inflammatory cells in mice treated with 
CVT-6883. (A) BAL fluid was collected from 
postnatal day 38 mice, and total cell numbers 
were counted. (B and C) BAL cells were cyto-
spun and stained with Diff-Quick, allowing for 
determination of cellular differentials. Data are 
mean cell counts ± SEM. *P ≤ 0.05 versus 
vehicle-treated ADA+ mice; #P ≤ 0.05 versus 
vehicle-treated ADA–/– mice. n = 8 (ADA+), 6–8 
(ADA–/–). (D) Increased numbers of foam cells 
were found by directly examining cytospun cells 
stained with Diff-Quick. Scale bars: 10 μm.    
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Production of proinflammatory cytokines. Transcript levels of various proinflammatory cytokines were measured in whole-lung extracts from 
postnatal day 38 mice using quantitative RT-PCR. Shown are levels of (A) TNF-α, (B) IL-6, (C) CXCL2, (D) CCL11, (E) CCL17, and (F) CXCL1. 
Results are presented as mean pg transcript/μg RNA ± SEM. *P ≤ 0.05 versus vehicle-treated ADA+ mice; #P ≤ 0.05 versus vehicle-treated 
ADA–/– mice. n = 4 (ADA+), 8 (ADA–/–). ND, not detected.    
Figure 5
CVT-6883 treatment inhibits alveolar airway enlargement in ADA–/– 
mice. Lungs from postnatal day 38 mice were infused with fixative 
under constant pressure (25 cm H2O) and processed for H&E staining. 
(A) Lung from an ADA+ mouse treated with vehicle. (B) Lung from an 
ADA+ mouse treated with CVT-6883. (C) Lung from an ADA–/– mouse 
treated with vehicle. (D) Lung from an ADA–/– mouse treated with CVT-
6883. Images are representative of 8 animals from each group. Scale 
bars: 100 μm. (E) Alveolar airspace size was calculated using Image-
Pro analysis software; data are mean chord length ± SEM. *P ≤ 0.05 
versus vehicle-treated ADA+ mice; #P ≤ 0.05 versus vehicle-treated 
ADA–/– mice. n = 5 per group.    
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CVT-6883 treatment inhibits the expression of genes associated with alveolar airway destruction. Transcript levels of TIMP-1 (A), MMP-9 (B), 
and MMP-12 (C) were measured in whole-lung RNA extracts from postnatal day 38 mice using quantitative RT-PCR. Data are mean pg tran-
script/μg RNA ± SEM. *P ≤ 0.05 versus vehicle-treated ADA+ mice; #P ≤ 0.05 versus vehicle-treated ADA–/– mice. n = 4 (ADA+), 8 (ADA–/–).    
Figure 7
Pulmonary fibrosis in ADA–/– mice treated with CVT-
6883. (A–C) Lung sections from postnatal day 38 
mice were stained with an antibody against α-SMA 
to visualize myofibroblast (brown stain). (A) Lung 
from an ADA+ mouse treated with vehicle. (B) Lung 
from an ADA–/– mouse treated with vehicle. (C) Lung 
from an ADA–/– mouse treated with CVT-6883. (D–F) 
Lung sections were stained with Masson’s trichrome 
to visualize collagen deposition (blue stain). (D) 
Lung from an ADA+ mouse treated with vehicle. (E) 
Lung from an ADA+ mouse treated with CVT-6883. 
(F) Lung from an ADA–/– mouse treated with vehicle. 
(G) Lung from an ADA–/– mouse treated with CVT-
6883. Sections are representative of 6 different 
mice from each treatment. Scale bars: 100 μm. (H) 
Whole-lung α1-procollagen transcript levels. Data 
are mean pg transcript/μg RNA ± SEM. (I) Soluble 
collagen protein levels. Data are mean μg collagen/
ml BAL fluid ± SEM. *P ≤ 0.05 versus vehicle-treat-
ed ADA+; #P ≤ 0.05 versus vehicle-treated ADA–/–. 
n = 4 (ADA+), 8 (ADA–/–).    
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A2BAR expression and adenosine levels in the lungs of 



















CVT-6883–treated ADA–/– mice had decreased expres-
sion of TGF-β1 and OPN in alveolar macrophages. RNA 
was extracted from whole lungs of postnatal day 38 
mice for analysis using quantitative RT-PCR for various 
fibrosis-associated transcripts. Results demonstrate that 
lungs from CVT-6883–treated ADA–/– mice had lower lev-
els of transcripts for TGF-β1 (A) and OPN (B) compared 
with that seen in the lungs of vehicle-treated ADA–/– mice. 
*P ≤ 0.05 versus ADA+; #P ≤ 0.05 versus vehicle-treated 
ADA–/–. n = 4 (ADA+), 8 (ADA+). (C–E) Immunolocaliza-
tion of TGF-β1. (F–H) Immunolocalization of OPN. Lung 
sections from vehicle-treated ADA+ mice (C and F), 
vehicle-treated ADA–/– mice (D and G), and CVT-6883–
treated ADA–/– mice (E and H) are shown. Arrows denote 
macrophages. Scale bars: 100 μm.    
Figure 9
A2BAR transcript and adenosine levels in the lungs. (A) RNA was extracted from whole 
lungs of postnatal day 38 mice for analysis of A2BAR expression using quantitative 
RT-PCR. Data are mean transcript levels ± SEM. *P ≤ 0.05 versus vehicle-treated 
ADA+; #P ≤ 0.05 versus vehicle-treated ADA–/–. n = 4 (ADA+), 8 (ADA–/–). (B) Adenine 
nucleotides were extracted from whole lungs of postnatal day 38 mice, and adenosine 
levels were quantified by reverse-phase HPLC. Data are mean fold increase ± SEM. 
*P ≤ 0.05 versus ADA+. n = 4 per group.    
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CVT-6883 treatment in a model of bleomycin-induced 
pulmonary injury. (A–C) Lung sections were stained with 
an antibody against α-SMA to visualize myofibroblast 
(brown). (D–F) Lung sections were stained with Masson’s 
trichrome to visualize collagen (blue). Shown are lungs 
from saline-treated mice 14 days after treatment (A and D) 
and bleomycin-treated mice 14 days after treatment that 
were treated with vehicle (B and E) or CVT-6883 (C and F) 
beginning on day 5 of the protocol. Sections are represen-
tative of 7 different mice from each treatment. Scale bars: 
100 μm. (G) Total BAL cells. Data are mean ± SEM. (H) 
Whole-lung collagen protein levels. Data are mean μg col-
lagen/lung ± SEM. *P ≤ 0.05 versus saline-treated mice; 
#P ≤ 0.05 versus vehicle-treated bleomycin-exposed mice. 
n = 7 per group.    
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